Lucid Diagnostics’ (LUCD) “Buy” Rating Reiterated at BTIG Research

BTIG Research reiterated their buy rating on shares of Lucid Diagnostics (NASDAQ:LUCD) in a research note published on Monday,Benzinga reports. They currently have a $2.50 price target on the stock.

LUCD has been the topic of a number of other research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lucid Diagnostics in a report on Monday, December 29th. Needham & Company LLC reissued a “buy” rating and issued a $3.00 price target on shares of Lucid Diagnostics in a report on Thursday, March 26th. Wall Street Zen upgraded shares of Lucid Diagnostics from a “sell” rating to a “hold” rating in a research report on Saturday, March 28th. Finally, Ascendiant Capital Markets upped their price target on shares of Lucid Diagnostics from $8.00 to $8.25 and gave the stock a “buy” rating in a report on Wednesday, December 10th. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Lucid Diagnostics currently has an average rating of “Moderate Buy” and a consensus price target of $3.94.

Lucid Diagnostics Price Performance

Shares of NASDAQ LUCD opened at $1.15 on Monday. The company has a market cap of $158.33 million, a P/E ratio of -1.20 and a beta of 1.24. Lucid Diagnostics has a 52 week low of $0.95 and a 52 week high of $1.80. The business has a 50-day simple moving average of $1.29 and a two-hundred day simple moving average of $1.18.

Lucid Diagnostics (NASDAQ:LUCD) last announced its quarterly earnings results on Thursday, March 26th. The company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.03). The firm had revenue of $1.50 million during the quarter, compared to analysts’ expectations of $1.39 million. Equities research analysts anticipate that Lucid Diagnostics will post -0.84 EPS for the current year.

Institutional Investors Weigh In On Lucid Diagnostics

A number of institutional investors and hedge funds have recently bought and sold shares of LUCD. Cubist Systematic Strategies LLC bought a new stake in Lucid Diagnostics during the first quarter valued at approximately $39,000. Goldman Sachs Group Inc. increased its holdings in shares of Lucid Diagnostics by 35.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 86,302 shares of the company’s stock worth $129,000 after buying an additional 22,727 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Lucid Diagnostics by 420.3% during the 2nd quarter. Geode Capital Management LLC now owns 1,577,369 shares of the company’s stock valued at $1,814,000 after buying an additional 1,274,194 shares in the last quarter. Intech Investment Management LLC purchased a new stake in shares of Lucid Diagnostics during the 2nd quarter valued at $42,000. Finally, JPMorgan Chase & Co. lifted its holdings in shares of Lucid Diagnostics by 71,026.1% during the 2nd quarter. JPMorgan Chase & Co. now owns 32,718 shares of the company’s stock worth $38,000 after acquiring an additional 32,672 shares during the last quarter. 74.01% of the stock is owned by hedge funds and other institutional investors.

Lucid Diagnostics Company Profile

Lucid Diagnostics is a molecular diagnostics company focused on improving early detection of oral and oropharyngeal cancers. The company’s flagship offering, the LucidDx Oral Cytology Brush Test, combines a minimally invasive brush biopsy tool with proprietary laboratory analysis to identify cellular abnormalities indicative of malignancy. Samples collected in dental and medical offices are sent to Lucid’s CLIA-certified and CAP-accredited laboratory, where advanced imaging and cytopathology workflows generate diagnostic reports for clinicians and patients.

Since commencing commercial operations, Lucid Diagnostics has worked to integrate its testing platform into dental practices, oral surgery clinics and ENT specialists across the United States.